Retevmo Treatment for medullary thyroid cancer

Availability in India

The active element in the cancer medication Retevmo is sepercatinib. Adult patients with one of the following conditions are treated with it: locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion; locally advanced or metastatic solid tumors with a RET gene fusion; advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. It exerts its effect via inhibiting kinase.It is also used in pediatric patients over 12 with advanced medullary thyroid cancer.

Retevmo cost in India is inexpensive and can be bought with a valid prescription, so you may get it from various sellers and spend less for the medication. Indian Pharma is one of the most reputable and trusted generic medicine manufacturers. 

Recommended Dosage

Selpercatinib is contained in Retevmo. The patient is chosen based on the presence of a certain RET gene mutation (MTC) or transfection gene rearrangement (NSCLC or thyroid). The dosage of retevmo is regulated by body weight. As a result, before beginning Retevmo medication, the patient's body weight is examined, and the Retevmo dosage is changed as needed. If the patient weighs less than 50 kg, the dose should be 120 mg; if the patient weighs 50 kg or more, the dose should be 160 mg. This medicine requires a prescription, and the therapy should be initiated and overseen by a certified medical specialist.

Dosage & Administration

Retevmo must be administered orally twice a day, approximately every 12 hours until disease progression or severe toxicity is noted. This drug can be taken with or without food unless combined with a proton pump inhibitor. It should be emphasized that Retevmo capsules should not be crushed or chewed but should instead be swallowed whole. If a dose is missed, it should be taken at least 6 hours after the previous dose. Please read the package leaflet or contact us at https://www.indianpharmanetwork.in/contact-us/  if you have any questions about missing Retevmo doses. 

An FDA approved drug

The drug Retevmo conatins Selpercatinib, approved by the FDA in 2020 for treating non-small cell lung cancer. SELPERCATINIB price is reasonable and one can buy this medicine from any liecnesed supplier. This drug is a RET inhibitor that belongs to the tyrosine kinase inhibitor class of cancer medicines. Retevmo inhibits the activity of abnormal proteins in the body. The body produces these proteins due to changes in the RET gene. certain abnormal proteins in people with certain mutations can lead to uncontrolled cell proliferation and malignancy, culminating in tumor formation. Selpercatinib reduces cancer cell growth and spread by blocking proteins.

Common side effects

Despite being a potent cancer treatment, Retevmo has some adverse effects that can be moderate or fatal. The most common adverse reactions seen after using Retevmo are loss of appetite, headache, dizziness, prolonged QT interval, high blood pressure, abdominal pain, diarrhea, nausea, vomiting, constipation, dry mouth, rash, fever, tiredness, oedema, bleeding, and laboratory blood tests showing changes in liver enzymes, decreased platelet and white blood cell count, decreased magnesium, and increased creatinine. One out of every 10 people taking this drug will experience these side effects.

Retevmo's most common main adverse effects are stomach pain, hypersensitivity, diarrhea, and blood tests that show elevations in liver enzymes, indicating liver stress. 

Drug Interactions

Certain drug interactions should be avoided because they can affect the Retevmo dose. Retevmo 40mg/80mg capsules have Some interactions, which are as follows:

Coadministration of acid-reducing medicines should be avoided since it reduces plasma selpercatinib levels and may decrease Retevmo anti-tumor activity.  

Coadministration of strong and moderate CYP3A inhibitors should be avoided since it raises selpercatinib levels in the blood and increases the risk of side effects.

 Strong and moderate CYP3A inducers: Avoid co administration since it lowers drug plasma concentration, which reduces Retevmo's anti-tumor activity.

Substrates for CYP2C8 and CYP3A: They increase plasma Retevmo levels. Co Administration should be avoided at all costs. Adjust the substrate dosage as stated on the product label if coadministration is unavoidable.

Certain P-gp Substrates: it improves Retevmo concentration as well. Coadministration should thus be avoided. Adjust the substrate dosage as stated on the product label if coadministration is unavoidable.

Retevmo: Summary of the medicine

Retevmo works by inhibiting kinases. The chemical formula for selpercatinib is C29H31N7O3, and its molecular weight is 525.61 g/mol. Selpercatinib is a white to light yellow powder that absorbs moisture from the air and is mildly hygroscopic. Selpercatinib's water solubility is pH dependent. It is only marginally soluble at low pH and virtually insoluble at neutral pH. 40 mg and Retevmo 80 mg hard gelatin capsules are available for oral use. Click here to learn more about selpercatinib and its numerous applications/pharmacological actions. Please contact us by phone or text at https://www.indianpharmanetwork.in/contact-us/. 

Storage & Handling of the medicine 

Microcrystalline cellulose and colloidal silicon dioxide are inactive ingredients in each medicine capsule. The 40 mg pill shell contains gelatin, titanium dioxide, ferric oxide black, and black ink. Patients must read the ingredients and notify their doctor if they cause allergies. Furthermore, the active ingredient is selpercatinib. Keep Retevmo capsules at room temperature, between 68°F and 77°F (20°C and 25°C). A Retevmo 40 mg bottle has 60 capsules.

Retevmo: Price in India

Pregnancy- Based on animal research and the mechanism of action of selpercatinib, it has been discovered that when taken by pregnant women, it can actively cause fetal harm. Pregnant women should avoid taking it as a result. Seek medical attention in an emergency. 

Lactation- No information is available on the presence of selpercatinib in milk. There have been no studies on its metabolites in human milk, their effects on breastfed children, or their effects on milk production. However, due to the likelihood of serious adverse reactions in breastfed children, it is recommended that nursing be discontinued during and one week after the last dosage of Retevmo treatment to avoid severe effects on the child.

Retevmo: Clinical studies

One of the most important studies illustrates the effects of sepercatinib. The researchers discovered that Retevmo effectively shrinks tumor size in patients with cancer caused by RET gene abnormalities. Individual effects of selpercatinib (Retevmo) were investigated in this study but not compared to other drugs, dummy therapies, or placebo. The medication shrinks tumors in all cases, whether they are advanced non-small cell lung cancer, advanced thyroid cancer, or advanced medullary thyroid cancer. This great drug is available for purchase from any licensed supplier. Furthermore, the Retevmo cost is inexpensive and reasonable, allowing them to be easily adopted.

This efficient treatment for non-small cell lung and thyroid/medullary thyroid cancer is now available in India. Retevmo treatment can begin after being diagnosed using an FDA-approved test by competent medical health professionals and doctors. It is important to remember that, despite its inexpensive Retevmo price, Retevmo is not a prescription medication. For the sale and purchase of Retevmo, legal authorization and prescription are required.